...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Shareholder Value

Totally agree with your take Toinv, the lack of skill demonstrated at CEO is appalling in both companies

Share
New Message
Please login to post a reply